尼塔佐化物通过调节STAT-3和NF-κB通路来缓解Wistar大鼠中CFA诱导的类风湿性关节炎
Pradyuman Prajapati1, Gaurav Doshi1
1Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India.
Rheumatology and immunology research
|April 7, 2025
概括
尼塔佐化物 (NTZ) 通过减少炎症和改善关节健康在老鼠模型中表现出显著的抗关节炎作用. 这项研究突出了NTZ的重点.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,导致关节疼痛和炎症.
- 肌痛性关节炎的发病包括核因子kappa B (NF-κB),介质素-6 (IL-6) 和瘤缩因子-α (TNF-α) 的升高.
- 这些因素通过STAT-3信号通路促进突炎症和关节破坏.
研究的目的:
- 为了评估Nitazoxanide (NTZ) 的抗关节炎潜力.
- 在关节炎的老鼠模型中研究NTZ对炎症和关节病理的影响.
主要方法:
- 使用了完全弗洛恩德辅助剂 (CFA) 诱导的关节炎的小鼠模型.
- 尼塔佐化物 (NTZ) 被口服剂量为100,200和400毫克/公斤,持续28天.
- 评估的参数包括脚胀,体重,关节炎指数,血液学,细胞因子水平和关节组织病理学.
主要成果:
- NTZ治疗显著减少了脚胀,胀和关节炎指数.
- 血液学分析显示白细胞数量减少,红细胞和血红蛋白水平增加.
- NTZ调节了炎症性细胞因子水平,改善了脚关节组织病理学.
结论:
- 尼塔佐化物 (NTZ) 具有显著的抗关节炎活性.
- NTZ通过抑制STAT-3和NF-κB信号通路而起作用.
- NTZ为类风湿性关节炎提供了潜在的治疗选择.
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
The JAK-STAT Signaling Pathway
8.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103


